SEARCH

LEGAL UPDATE

Extension of patent protection in Switzerland following paediatric trials

Supplementary protection certificates compensate for delay to market entry for products (medicinal or plant protection) in the European Union and some European Economic Area states by providing up to an additional five years of protection beyond patent expiry.

LEGAL UPDATE

AG recommends narrow interpretation of Neurim in Abraxis

In the on-going case of Abraxis v Comptroller General of Patents, Advocate General Saugmandsgaard Øe proffered his non-binding opinion at the Court of Justice of the European Union concerning Supplementary Protection Certificates for new formulations of medicinal products.